Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients
Open Access
- 1 January 2011
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 15 (5), R257
- https://doi.org/10.1186/cc10518
Abstract
Only limited information exists on the pharmacokinetics of prolonged (> 24 hours) and high-dose dexmedetomidine infusions in critically ill patients. The aim of this study was to characterize the pharmacokinetics of long dexmedetomidine infusions and to assess the dose linearity of high doses. Additionally, we wanted to quantify for the first time in humans the concentrations of H-3, a practically inactive metabolite of dexmedetomidine. Thirteen intensive care patients with mean age of 57 years and Simplified Acute Physiology Score (SAPS) II score of 45 were included in the study. Dexmedetomidine infusion was commenced by using a constant infusion rate for the first 12 hours. After the first 12 hours, the infusion rate of dexmedetomidine was titrated between 0.1 and 2.5 μg/kg/h by using predefined dose levels to maintain sedation in the range of 0 to -3 on the Richmond Agitation-Sedation Scale. Dexmedetomidine was continued as long as required to a maximum of 14 days. Plasma dexmedetomidine and H-3 metabolite concentrations were measured, and pharmacokinetic variables were calculated with standard noncompartmental methods. Safety and tolerability were assessed by adverse events, cardiovascular signs, and laboratory tests. The following geometric mean values (coefficient of variation) were calculated: length of infusion, 92 hours (117%); dexmedetomidine clearance, 39.7 L/h (41%); elimination half-life, 3.7 hours (38%); and volume of distribution during the elimination phase, 223 L (35%). Altogether, 116 steady-state concentrations were found in 12 subjects. The geometric mean value for clearance at steady state was 53.1 L/h (55%). A statistically significant linear relation (r2 = 0.95; P < 0.001) was found between the areas under the dexmedetomidine plasma concentration-time curves and cumulative doses of dexmedetomidine. The elimination half-life of H-3 was 9.1 hours (37%). The ratio of AUC0-∞ of H-3 metabolite to that of dexmedetomidine was 1.47 (105%), ranging from 0.29 to 4.4. The ratio was not statistically significantly related to the total dose of dexmedetomidine or the duration of the infusion. The results suggest linear pharmacokinetics of dexmedetomidine up to the dose of 2.5 μg/kg/h. Despite the high dose and prolonged infusions, safety findings were as expected for dexmedetomidine and the patient population. ClinicalTrials.gov: NCT00747721.Keywords
This publication has 17 references indexed in Scilit:
- Rate and Extent of Drug Accumulation after Multiple Dosing RevisitedClinical Pharmacokinetics, 2010
- Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unitCritical Care Medicine, 2010
- Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G‐Dex‐1 and G‐Dex‐2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detectionRapid Communications in Mass Spectrometry, 2004
- National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and StratificationAnnals of Internal Medicine, 2003
- The Richmond Agitation–Sedation ScaleAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care †British Journal of Anaesthesia, 2002
- Influence of Cardiac Output on Dexmedetomidine PharmacokineticsJournal of Pharmaceutical Sciences, 2000
- A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter studyJama-Journal Of The American Medical Association, 1993
- ALPHA 2 ADRENOCEPTOR AGONISTS AND ANAESTHESIABritish Journal of Anaesthesia, 1993
- The Pharmacokinetics and Hemodynamic Effects of Intravenous and Intramuscular Dexmedetomidine Hydrochloride in Adult Human VolunteersAnesthesiology, 1993